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Abstract
Background: Tissue fibrosis is an integral component of chronic inflammatory (liver and pancreas) diseases and 
pancreatic cancer. Activated pancreatic- (PSC) and hepatic- (HSC) stellate cells play a key role in fibrogenesis. To identify 
organ- and disease-specific stellate cell transcriptional fingerprints, we employed genome-wide transcriptional analysis 
of primary human PSC and HSC isolated from patients with chronic inflammation or cancer.
Methods: Stellate cells were isolated from patients with pancreatic ductal adenocarcinoma (n = 5), chronic pancreatitis 
(n = 6), liver cirrhosis (n = 5) and liver metastasis of pancreatic ductal adenocarcinoma (n = 6). Genome-wide 
transcriptional profiles of stellate cells were generated using our 51K human cDNA microarray platform. The identified 
organ- and disease specific genes were validated by quantitative RT-PCR, immunoblot, ELISA, immunocytochemistry 
and immunohistochemistry.
Results: Expression profiling identified 160 organ- and 89 disease- specific stellate cell transcripts. Collagen type 11a1 
(COL11A1) was discovered as a novel PSC specific marker with up to 65-fold higher expression levels in PSC compared 
to HSC (p < 0.0001). Likewise, the expression of the cytokine CCL2 and the cell adhesion molecule VCAM1 were 
confined to HSC. PBX1 expression levels tend to be increased in inflammatory- vs. tumor- stellate cells. Intriguingly, 
tyrosine kinase JAK2 and a member of cell contact-mediated communication CELSR3 were found to be selectively up-
regulated in tumor stellate cells.
Conclusions: We identified and validated HSC and PSC specific markers. Moreover, novel target genes of tumor- and 
inflammation associated stellate cells were discovered. Our data may be instrumental in developing new tailored 
organ- or disease-specific targeted therapies and stellate cell biomarkers.
Introduction
Emerging body of data suggest a critical role for stellate
cells in the pathophysiology of pancreatic cancer and
chronic inflammatory diseases [1-5]. Hepatic stellate cells
(HSC) were first described by Karl von Kupffer in 1876,
however similar cells in the pancreas were first observed
in 1980s [1,3,6]. In 1998 Bachem and Apte isolated and
cultured pancreatic stellate cells (PSC) [7,8]. Morpho-
logic, functional and gene expression studies revealed
that PSC resemble HSC characteristics and therefore may
possibly share a common origin [3,9]. However, the origin
of stellate cells is still controversially debated. Mesenchy-
mal [10,11], endodermal [12,13] as well as neuroectoder-
mal origins [14-16] are suggested. Further, it is postulated
that in the diseased organ, stellate cells are transformed
from their quiescent precursors, or recruited from local
fibroblasts, bone marrow derived cells or generated via
epithelial-mesenchymal transformation [1,3,17].
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HSC represent 5-8% of all human liver cells and reside
in the space of Disse [1]. In contrast to quiescent HSC,
activated HSC lack cytoplasmic lipid droplets containing
retinyl esters and long cytoplasmic processes. Their acti-
vation or trans-differentiation is regulated by paracrine
and autocrine loops of growth factors which are associ-
ated with pathological conditions such as liver injury, cir-
r h o s i s  a n d  c a n c e r  [ 1 , 2 ] .  S t e l l a t e  c e l l  o v e r - a c t i v i t y  c a n
severely impair organ function due to excessive contrac-
tion and abundant extracellular matrix protein deposi-
tion. Moreover, it is becoming clearer that myofibroblasts
found in the activated stroma of epithelial tumors signifi-
cantly impact tumor behavior [5,18]. Tumor-stroma
interactions influence both the progression of cancer and
tumor responses to cancer therapies [4,5,18-21]. Since
conventional therapies are far from cure, new targeted
therapies appear as promising alternatives or adjuncts
[22]. Indeed, the tumor microenvironment and the des-
moplastic reaction observed in pancreatic ductal adeno-
carcinoma (PDAC) have attracted enormous scientific
attention and emerged as a critical therapeutic target
[19,23,24].
To selectively and specifically target HSC or PSC in
chronic inflammatory diseases or in cancer, a better
molecular characterization of these cells is required. In an
attempt to identify organ- and disease-specific tran-
scripts, we isolated stellate cells from a total of 22 patients
with primary PDAC, chronic pancreatitis, liver cirrhosis,
and liver metastasis of PDAC. Genome-wide transcrip-
tional analysis was employed and novel candidate tumor-,
inflammation- or organ-specific stellate cell genes were
identified and validated in the tissues of these patients by
real time quantitative RT-PCR, immunohistochemistry,
immunocytochemistry, ELISA and immunoblot analyses.
Materials and methods
Pancreatic tissues and human pancreatic stellate cell 
cultivation
The use of human material for the analysis was approved
by the local ethics committee of the University of Heidel-
berg, Germany, and written informed consent was
obtained from all patients. Sterile tissues were obtained
immediately after surgical resection from five patients
with PDAC, six patients with chronic pancreatitis (CP),
five patients with liver cirrhosis (LC) that underwent liver
transplantation, and six patients with liver metastasis
(LM) of pancreatic cancer. During tissue collection,
freshly removed samples were either snap frozen in liquid
nitrogen and stored at -80°C for protein and DNA extrac-
tion or preserved in RNA-later solution for future RNA
extraction. A portion of the samples was also fixed in 4%
parafomaldehyde solution for 12-24 h and then embed-
ded in paraffin for histological analysis. Human stellate
cell isolation and cultivation were performed under ster-
ile conditions for all cell types by using the outgrowth
method as described initially by Bachem et al. [8]. Briefly;
passage-1 was described as the first lot of cells growing
out from fibrotic blocks of pancreatic tissues seeded in 10
cm Petri dishes. To prevent bias, the number of blocks
was kept constant (30 blocks with 2-3 mm diameter/per
75 cm2). Passage-2 is a 1:2 division of these cells into two
new T75 cm2 flasks. When passage-2 cells reached con-
fluency, they were aliquoted and frozen. All cells used
were passage-3 after thawing a clone of frozen passage-2.
Purity of stellate cells was routinely checked by immuno-
cytochemistry and immunofluorescence analyses (Addi-
tional file1). All passages used were controlled and no
morphologically different subpopulation was detected.
Total RNA isolation
To prevent passage dependent variations, third passages
of PSC and HSC were used for all analyses. Total RNA
from 80% confluent stellate cells in 10 cm Petri dishes was
isolated by organic extraction with the phenolic Trizol
reagent as described [25]. The Agilent 2100 Bioanalyzer
(Agilent Technologies Inc. Santa Clara, CA) was used for
the quality control of the isolated total RNA and ampli-
fied RNA (aRNA) by capillary electrophoretic separation
[26].
Genome-wide expression profiling
Genome-wide expression profiling was done using 51K
Human Unigene III cDNA microarrays. The microarrays
were designed, generated, and hybridized as described
previously [24,26,27]. Each sample was hybridized against
Human Universal Reference Total RNA (# 636538, BD
Clontech, Heidelberg, Germany). Expression profiling
was performed as previously described with minor modi-
fications [24,26,27]. Linear amplification from 2 μg total
RNA was performed using the "MessageAmp II aRNA
Amplification Kit" (Ambion, #1751). From amplified
RNA, 5 μg were used for indirect labeling by incorpora-
tion of aminoallyl modified nucleotides and chemical
attachment of free reactive fluorescent Cy3- or Cy5-dye
(Atlas Glass fluorescent labelling kit, BD Biosiences Cata-
logue #K1037-1; Cy5-dye, Cy3-dye, GE Healthcare UK
Limited, #Q15108, #Q13108). Corresponding Cy3- and
Cy5- labeled probes and competitor DNA (5 μg human
Cot-DNA, Invitrogen; 5 μg poly-dA, Amersham) were
combined, diluted in hybridization buffer to a final vol-
ume of 80 μl (50% Formamide, 6× SSC, 0.5% SDS, 5×
Denhards), and denatured for 5 min at 95°c prior to
hybridization. Prehybridization was performed at 42°C
for 20 min in 6× SSC, 0.5% SDS, 1% BSA. Slides were
rinsed in H2O and spotted probes were denatured by
incubating the slide for 2 min in 90°C H2O. Hybridization
probe was added and static hybridization performed at
42°C for 16 h. Excess of probe was removed by washing inErkan et al. Molecular Cancer 2010, 9:88
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2 × SSC, 0.5%SDS at 42°C for 5 min, then in 0.2 × SSC,
0.5%SDS at 42°C for 15 min and finally in isopropanol for
30s at RT . Slides were scanned with Agilent Microarray
Scanner and image processing was done using the "Chip-
skipper" software. Data were stored in MO-MEX data-
base Bloader that enables direct submission of large
batches of MIAME complaint expression profiling data to
the ArrayExpress database. Microarray data are available
online at ArrayExpress http://www.ebi.ac.uk/arrayex-
press under the accession no. E-TABM-625.
Statistical analysis of the microarray data
Generation of expression matrices, data annotation, fil-
tering, and processing were done using TableButler soft-
ware package http://www.oncoexpress.de/software/
tablebutler. All microarray statistics including t-test with
permutation analysis, Pavlidis template matching (PTM),
and cluster analysis were done using the Java based soft-
ware package TIGR MultiExperiment Viewer (TMEV)
version 3.01 http://www.tm4.org/mev.html. Genes were
defined as differentially expressed between two sets of
samples if a two-class permutation based t-test (number
of permutations = 1000) yielded a p-value of less than
0.05 after standard Bonferroni correction for multiple
hypothesis testing. Subsequently, regulated genes were
sorted by hierarchical clustering (HCL). PTM allows the
specification of a template expression profile for a gene by
designating relative gene expression ratios for each condi-
tion. The data sets are searched for matches to this tem-
plate, i.e. for the specific expression pattern. Gene
expression data were filtered for genes that matched each
template based on a Pearson correlation coefficient r ≥
0.70. The obtained gene expression profiles were visual-
ized as heatmaps.
Real time quantitative PCR
All reagents and equipment for mRNA/cDNA prepara-
tion were purchased from Roche Applied Science Diag-
nostics (Mannheim, Germany). mRNA extractions were
prepared by automated isolation using the MagNA Pure
LC instrument and isolation kit I. cDNA was prepared
using the first-strand cDNA synthesis kit (AMV) accord-
ing to the manufacturer's instructions. Real-time PCR
was performed with the Light Cycler Fast Start DNA
SYBR Green kit. All primers were obtained from Search-
LC (Heidelberg, Germany). The calculated number of
specific transcripts was normalized to 10,000 copies of
the housekeeping gene PPIB (peptidylprolyl isomerase B,
also known as cyclophilin B), and expressed as number of
copies per μl of input cDNA. Statistical comparisons were
made by Mann-Whitney U test. A P-value less than 5%
was regarded as significant.
Immunohistochemistry and immunocytochemistry 
analyses
IHC was performed as described before [28]. Antibodies
used and the dilution ratios are shown in Table 1. Immu-
nocytochemistry analysis was performed using a previ-
ously described protocol [29].
Immunoblot analysis and densitometry
To keep passage dependent variations at minimum, third
passages of PSC and HSC were used for analysis. Stellate
cells were grown in Petri dishes until 80% confluency
under standard conditions. Protein extraction was car-
ried out as published before [28]. Immunoblot analyses
and the densitometric analysis of the blots were done as
described previously [30]. Antibodies used and the
appropriate dilution are shown in Table 1. Graphic results
are expressed after normalization to the housekeeping
Table 1: The antibodies used and the appropriate dilutions.
COL11a1 VCAM1 CELSR3 Pbx1
Company Santa Cruz
(sc-68853)
Santa Cruz
(sc-8304)
Abcam (ab12958)
Santa Cruz (sc-46849)
Abcam
(ab12001)
Host Rabbit Rabbit Rabbit (Abcam)
Goat (Santa Cruz)
Rabbit
Immunohistochemistry 1:500 1:200 1:100 (Abcam) 1:100
Immunoblot na 1:250 1:250 (Santa Cruz) 1:100
Immunocytochemistry 1:100 Na Na na
na: not applicableErkan et al. Molecular Cancer 2010, 9:88
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gene GAPDH as percent change of the appropriate con-
trol.
ELISA
Cells were grown in 10-cm plates until 80% confluence.
Serum free medium was kept on the cells for 48 h. Super-
natants and total cell lysates were extracted and frozen at
-80°C until use. For the quantification of CCL2, a com-
mercially available ELISA kit (Human MCP-1 ELISA,
555179, BD Biosciences, Heidelberg, Germany) was used
according to the manufacturers' recommendations.
Results
Evaluation of gene expression profiles
Morphology and purity of stellate cells was routinely
checked by immunocytochemistry (Additional file1). In
order to identify organ and disease specific transcriptome
signatures of stellate cells, a microarray analysis was
made (Figure 1, Figure 2). The obtained gene expression
profiles were visualized as heatmaps (Figure 3, Figure 4).
Red signifies high gene expression, while black signifies
intermediate gene expression and green signifies low
gene expression of the corresponding gene compared to
the reference, respectively. Each row represents one gene,
each column represents one sample. The dendrograms
on the left side of the heat maps define how the genes
cluster after applying hierarchical cluster analysis (aver-
age linkage). Expressions of genes are expressed using
log2 ratios, where the +/- sign indicates which channel
had the higher intensity. Hence, an expression ratio of +2
represents a 4-fold up-regulation of a gene under condi-
tion A compared to this gene under condition B, an
expression ratio of -2 represents a 4-fold down-regula-
tion.
Organ specific profile
A total of 160 annotated genes were identified as differen-
tially expressed between pancreas and liver derived stel-
late cells. To obtain a clear and well-defined matrix, these
genes were compared as: downregulated in pancreatic
stellate cells in comparison to hepatic stellate cells (n =
80, Figure 3B) or upregulated in pancreatic stellate cells in
comparison to hepatic stellate cells (n = 80, Figure 3C). A
group of selected genes are presented in Table 2. Signifi-
cantly different genes in each group with high differential
expression ratios were further analyzed by quantitative
real time PCR, immunoblotting, immunocytochemistry
and immunohistochemistry in all patients.
Pancreatic stellate cell specific genes
In this group, collagen type XI alpha 1 (Col11a1) was the
most specific gene with a 13.74-fold upregulation in PSC
compared to HSC. In concordance with the array data,
Col11a1 was highly pancreas specific with its average
mRNA expression being 65-fold (p < 0.0001) higher in the
PSC compared to that of HSC as determined by qRT-PCR
(Figure 5A). Since there was no suitable antibody for
immunoblot analysis, the expression of Col11a1 in tissues
and in cultured stellate cells was evaluated by immunohis-
tochemistry and immunocytochemistry. In all patients,
PSC showed a specific staining while HSC remained
Col11a1 negative by immunohistochemistry. Co-localiza-
tion of alpha-smooth muscle actin (red) and Col11a1
(green) in stellate cells in pancreatic tissues is shown by
immunofluorescence analysis (Figure 5B). There was also a
weak staining in pancreatic acini and hepatocytes (Figure
5C-H). Verification of Col11a1 protein expression in cul-
tured stellate cells by immunocytochemistry showed also a
PSC specific staining (Figure 6).
Hepatic stellate cell specific genes
In this group, some genes showed a high HSC specificity.
Vascular cell adhesion molecule 1 (VCAM1) was 5.05-
f o l d  u p r e g u l a t e d  i n  H S C  c o m p a r e d  t o  P S C  a n d
chemokine (C-C motif) ligand 2 (CCL2) was 2.96-fold
upregulated in HSC compared to PSC. In line with the
microarray data compared to their average expressions in
PSC, VCAM1 and CCL2 mRNA expressions were 5.66-
fold (p = 0.0016) and 2.28-fold (p = 0.0020) higher in HSC
as det e rm ined by qR T -PCR,  r es pecti ve ly ( F igur e  7A &
Figure 8D). Next, to quantify the protein expression in
vitro, cell lysates of cultured human stellate cells (n = 4
p e r  p a t h o l o g y )  w e r e  a n a l y z e d  b y  i m m u n o b l o t t i n g  o r
ELISA. Protein expression of VCAM1 in cultivated stel-
Figure 1 Schematic expression of the hypothesis: Organ specific 
expression profile (pancreas vs. liver) of stellate cells.
organ specific expression
pancreas specific liver specific
PC CP LM LC
A
Figure 2 Schematic expression of the hypothesis: Disease specif-
ic expression profile (tumor vs. inflammation) of stellate cells.
disease specific expression
tumor specific inflammation specific
PC LC CP LM
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late cells mirrored its mRNA expression. Densitometric
analysis of samples showed a 4.71-fold (p = 0.028) higher
expression in HSC compared to that of PSC (Figure 7B).
Since there was no suitable antibody for immunoblot
analysis for CCL2, quantification was made by ELISA.
Similar to VCAM1 expression, CCL2 also showed a HSC
specific expression irrespective of the pathology (3.15-
fold, p = 0.024, Figure 8E). In the last step, we verified the
localization of these proteins in human tissues. Liver cir-
r h o s i s  t i s s u e s  w e r e  p r o b e d  w i t h  a l p h a - s m o o t h  m u s c l e
actin (Figure 8A) or VCAM-1 (Figure 8B). Co-localiza-
tion of alpha-smooth muscle actin (red) and VCAM-1
(green) in stellate cells (orange) in hepatic tissues is
shown by immunofluorescence analysis (Figure 8C). All
patients showed various degrees of VCAM1 expression.
Although immunohistochemistry showed specific stain-
ing in stellate cells, there was no obvious organ predilec-
tion. In addition to stellate cells, pancreatic cancer cells,
hepatocytes and some inflammatory cells were also posi-
tive for VCAM1 (Figure 7C-H).
Disease specific profile
Microarray analysis further identified a total of 89 anno-
tated genes as differentially expressed between stellate
cells derived from inflammatory and malignant condi-
tions (Figure 2). To obtain a clear and well-defined
matrix, these genes were sorted by two given expression
profiles as: downregulated in stellate cells of inflamed tis-
sues compared to stellate cells of tumor tissues (n = 25,
Figure 4B) or upregulated in inflamed tissue compared to
Figure 3 Heatmaps showing organ specific stellate cell genes: The mRNA expression profile of stellate cells from 22 patients was analyzed 
to identify organ specific changes. Heatmaps depict the hierarchically clustered genes that are downregulated in pancreatic stellate cells in com-
parison to hepatic stellate cells (B) and that are upregulated in pancreatic stellate cells in comparison to hepatic stellate cells (C). Upregulated levels 
of gene expression are displayed as red bars; downregulated levels are displayed as green bars. Black bars indicate intermediate level of gene expres-
sion.
C B
pancreas liver
-3.0 +3.0 0.0
-2.0 +2.0 0.0
pancreas liverErkan et al. Molecular Cancer 2010, 9:88
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tumor tissues (n = 64, Figure 4C). Significantly different
genes in each group with high differential expression
ratios were further analyzed by quantitative real time
PCR, immunoblotting, immunocytochemistry and
immunohistochemistry in all patients. A group of
selected genes are presented in Table 3.
Tumor specific genes
Microarray analysis showed that some genes displayed a
cancer specific pattern irrespective of the organ the stel-
late cells were derived from. For example, cadherin EGF
LAG seven-pass G-type receptor 3 (CELSR3) was 3.04-
fold upregulated in tumor associated stellate cells com-
pared to inflammation associated stellate cells. Similarly,
its mRNA expression was 123% higher (p = 0.004) in the
cancer associated stellate cells as determined by qRT-
PCR (Figure 9A). By immunoblot analysis, CELSR3 pro-
tein was expressed at 83% higher levels (p = 0.030) in
tumor related stellate cells compared to that of inflamma-
tion related stellate cells (Figure 9B). There was also a dis-
ease specific expression of CELSR3 expression in tissues
(Figure 9C-F). While hepatocytes were mostly unstained
some pancreatic acini and pancreatic cancer cells were
also positive for CELSR3.
Inflammation specific genes
In the microarray analysis, pre-B-cell leukemia transcrip-
tion factor 1 (Pbx1) was 1.7-fold upregulated in inflam-
mation associated stellate cells compared to tumor
associated stellate cells. Although the differences did not
reach statistical significance, Pbx1 expression was also
98% higher (p = 0.107) in inflammation associated stellate
cells as determined by qRT-PCR (Figure 10A). Similarly,
the protein expression of Pbx1 was also 64% higher in
stellate cells derived from inflammatory pathologies com-
pared to that of tumor derived stellate cells (p = 0.70, Fig-
Figure 4 Heatmaps showing disease specific stellate cell genes: The mRNA expression profile of stellate cells from 22 patients was ana-
lyzed to identify disease specific changes. Heatmaps depict the hierarchically clustered genes that are downregulated in inflamed tissue in com-
parison to tumor tissue (B) and that are upregulated in inflamed tissue in comparison to tumor tissue (C). Upregulated levels of gene expression are 
displayed as red bars; downregulated levels are displayed as green bars. Black bars indicate intermediate level of gene expression.
C B
-2.0 +2.0 0.0
-2.0 +2.0 0.0
inflammation tumor inflammation tumorErkan et al. Molecular Cancer 2010, 9:88
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ure 10B). Although partly discrepant with the
immunoblot analysis, this tendency was also visible by
immunohistochemistry analysis (Figure 10C-F). In addi-
tion to stellate cells, tubular complexes in pancreatic tis-
sues and bile ducts in the liver parenchyma also displayed
some Pbx1 positivity.
Discussion
Here we report the identification of novel tumor stellate
cell specific genes and proteins. In addition, hepatic vs.
pancreatic stellate cell specific transcripts were discov-
ered. The mRNA and protein expression levels of candi-
date genes identified by genome-wide transcriptional
Table 2: A group of highly differentially expressed genes between liver and pancreas stellate cells are shown.
Gene Name Description RefSeq ID Fold-change
ORGAN-SPECIFIC DIFFERENCES IN GENE EXPRESSION
Liver specific transcripts (High in HSC compared to PSC)
VCAM1 vascular cell adhesion molecule 1 NM_001078 5.05
PCOLCE2 procollagen C-endopeptidase enhancer 2 NM_013363 4.69
SOX17 SRY (sex determining region Y)-box 17 NM_022454 3.54
GATA4 GATA binding protein 4 NM_002052 3.41
TTC8 tetratricopeptide repeat domain 8 NM_144596 3.02
CCL2 chemokine (C-C motif) ligand 2 NM_002982 2.96
SEC23IP SEC23 interacting protein NM_007190 2.92
CCL11 chemokine (C-C motif) ligand 11 NM_002986 2.85
Pancreas specific transcripts (High in PSC compared to HSC)
COL11A1 collagen, type XI, alpha 1 NM_080629 13.74
EFNB3 ephrin-B3 NM_001406 4.83
SERTAD4 SERTA domain containing 4 NM_019605 4.29
EGLN2 egl nine homolog 2 (C. elegans) NM_053046 4.00
CDKN2B cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) NM_004936 3.56
CPE carboxypeptidase E NM_001873 3.54
CHKA choline kinase alpha NM_001277 3.31
FBLN1 fibulin 1 NM_001996 3.26
RefSeq ID: Reference Sequence identity; The National Center for Biotechnology Information (NCBI); http://www.ncbi.nlm.nih.gov/RefSeq. The 
fold-changes display the regulation of expression of the particular gene in stellate cells that is upregulated with respect to comparator.Erkan et al. Molecular Cancer 2010, 9:88
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analysis were confirmed by qRT-PCR, ELISA and Immu-
noblot analyses. The specific expression pattern of the
candidate proteins was further assured in-vitro by immu-
nocytochemistry of isolated stellate cells and ex-vivo by
immunohistochemistry of formalin fixed paraffin embed-
ded tissues. The identified molecular fingerprint of stel-
late cells might be instrumental in development of novel
biomarkers and rational design of therapeutic strategies
aiming to selectively target cancer or inflammation asso-
ciated stellate cells. One drawback of this study is the
absence of a third comparator, namely stellate cells from
the normal pancreas and liver. However, stellate cells
from the normal pancreas do not grow efficiently when
propagated by the outgrowth method. Neither could stel-
late cells from fibrotic tissues like chronic pancreatitis
and pancreatic cancer be efficiently propagated by colla-
genase digestion and centrifugation. The yield of the lat-
ter method is very low in comparison to the outgrowth
method. Therefore the authors have decided to use only
one stellate cell propagation method (outgrowth) to pre-
vent bias that may result from differences in methodol-
Figure 5 Quantitative mRNA analysis of Collagen11a1 and its localization in tissues and cultured stellate cells. Quantitative real-time PCR (A) 
was performed with the Light Cycler Fast Start DNA SYBR Green kit. The organ specific expression of Collagen11a1 is depicted in the last two columns 
of the graph. Double-staining and ex vivo immunofluorescence analysis is used to evaluate the colocalization (orange) of the typical stellate cell mark-
er α-SMA (red) and Collagen11a1 (green) in activated stellate cells of pancreatic cancer tissues (B, 630×). Tissues of primary pancreatic ductal adeno-
carcinoma (C, 200×, D, 50×), chronic pancreatitis (E, 200×), liver cirrhosis (F, 200×) and liver metastasis of pancreatic ductal adenocarcinoma (G, 200×, 
H, 50×) were immunostained with a specific antibody against Collagen11a1. Negative controls are shown as insets. Arrows show the stellate cells/
myofibroblasts in the fibrotic parts of the tissues.
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Figure 6 Expression analysis of Collagen11a1 in cultivated stel-
late cells: Immunocytochemistry was used to analyze 
Collagen11a1 expression in cultured stellate cells derived from 
tissues of primary pancreatic ductal adenocarcinoma (A, 400×), 
chronic pancreatitis (B, 400×), liver cirrhosis (C, 400×) and liver 
metastasis of pancreatic ductal adenocarcinoma (D, 400×). Cells 
were seeded on Teflon covered slides, fixed, permeabilized and immu-
nostained with a specific antibody against collagen type 11a1. Nega-
tive controls are shown as insets.
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ogy. As a trade-off, a comparator (normal stellate cells)
could not be used.
Among the here identified tumor stellate cell specific
genes,  JAK2  and  CELSR3  pose interesting targets for
developing therapeutic strategies. Aberrant JAK2 signal-
ing has been linked to myeloproliferative disorders such
as polycythemia vera and chronic myelogenous leukemia
[31,32]. Small molecular inhibitors of JAK2 signaling have
already entered clinical trials. Therefore the role of JAK2
overexpression in PSC of PDAC tumors remains to be
functionally elucidated. Upregulation of CELSR3 in
tumor PSC could also provide a potential druggable tar-
get since the protein encoded by this gene is located at
the plasma membrane and has intriguing signaling capa-
bilities [33]. CELSR3 is a member of the flamingo protein
subfamily which is part of the cadherin superfamily. The
flamingo cadherins have nine cadherin domains, seven
epidermal growth factor-like repeats and two laminin A
G-type repeats in their ectodomain [34]. It is postulated
that these proteins are receptors involved in contact-
mediated communication, with cadherin domains acting
as homophilic binding regions and the EGF-like domains
involved in cell adhesion and receptor-ligand interac-
tions. Together, these data suggest an important role for
CELSR3 in tumor stellate cells that warrants further
investigation.
Recent studies have reported differential regulation of
genes in murine and human stellate cells throughout their
activation process and under certain drug therapies.
Although these studies provide valuable information, a
careful interpretation of their data is warranted. First,
murine stellate cells may not reflect the situation in
humans due to interspecies differences. Second, stellate
cells show a great variance depending on the donor,
Figure 7 Quantitative mRNA and protein expression analysis of VCAM1 and its localization in tissues. Quantitative real-time PCR (A) was per-
formed with the Light Cycler Fast Start DNA SYBR Green kit. Densitometric analysis of immunoblots (B) were performed using the ImageJ program 
provided by the National Institutes of Health. Optic densities were corrected for the individual background noise and the matching equal loading 
densities. Each column represents one patient. For each entity, stellate cells from four different patients were evaluated. The organ specific expression 
of VCAM1 is depicted in the last two columns of each graph. Tissues of primary pancreatic ductal adenocarcinoma (C, 200×, D,50×), chronic pancre-
atitis (E, 200×), liver cirrhosis (F, 200×) and liver metastasis of pancreatic ductal adenocarcinoma (G, 200×, H, 50×) were immunostained with a specific 
antibody against VCAM1. Arrows show the stellate cells in the fibrotic parts of the tissues. Negative controls are shown as insets.
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therefore a weakness of the past studies might be the lim-
ited number of patients' stellate cells investigated to cover
the inter-individual heterogeneity. Our report constitute
one of the most comprehensive studies on stellate cell
transcriptome using 22 different human donors, thus
diminishing potential patient specific biases. This might
be a plausible explanation for the success of our approach
to identify organ- and disease-specific stellate cell tran-
scriptome. In contrast to the studies comparing quiescent
vs. activated stellate cells, we compared human stellate
cells that were activated in-vivo either by chronic inflam-
mation or cancer. Currently there is no information on
how the "ancestral microenvironmental activity" of stel-
late cells affects their transcriptome after in-vitro cultiva-
tion. Therefore, the identified tumor stellate cell specific
genes e.g. CELSR3 might provide a favorable therapeutic
profile to selectively target tumor stroma while sparing
the stellate cell activity under physiological conditions.
It has been reported that experimental ablation of
tumor associated fibroblasts or down-regulation of the
hedgehog-signalling pathway in the pancreatic tumor
stroma decreased cancer cell growth and greatly
increased intra-tumoral uptake of chemotherapeutic
drugs in murine models of colon, breast cancer an pan-
creatic cancers [5,35]. It is likely that targeting the stroma
in order to uncouple stromal-cancer cell interactions may
interrupt multiple aberrant autocrine and paracrine path-
ways that promote pancreatic cancer cell growth, inva-
sion and metastasis [4,21]. Currently, there is no stellate
cell specific promoter known to specifically target the
stromal cells in the liver or pancreas. Moreover, the simi-
larities between PSC and HSC make it very difficult to
target one population without creating side-effects on the
other one. For example, the usage of retinoids seems
promising in deactivating PSC in-vitro [36]. In contrast,
treatment with retinoids were shown to provoke fibro-
Figure 8 Co-localization of alpha smooth muscle-actin and VCAM1 molecules in hepatic stellate cells and quantitative mRNA and protein 
expression analysis of CCL2. In liver cirrhosis tissues, immunohistochemisty analysis was performed with antibodies against α-SMA (A, 400×) and 
VCAM1 (B, 400×). Double-staining and ex vivo immunofluorescence analysis was used to evaluate the co-localization (orange) of the typical stellate 
cell marker α-SMA (red) and VCAM-1 (green) in activated stellate cells of liver cirrhosis tissues (C, 630×). Quantitative real-time PCR (A) was performed 
with the Light Cycler Fast Start DNA SYBR Green kit. (B) A commercial ELISA kit was used to measure the CCL2 protein in the cell lysates of cultured 
stellate cells. The disease specific expression of CCL2 is depicted in the last two columns of each graph.
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Table 3: A group of highly differentially expressed genes between inflammation and cancer-associated stellate cells are 
shown.
Gene Name Description RefSeq ID Fold-change
DISEASE-SPECIFIC DIFFERENCES IN GENE EXPRESSION
Tumor specific transcripts (High in tumor compared to inflammation)
CELSR3 cadherin, EGF LAG seven-pass G-
type receptor 3
NM_001407 3.04
SYT13 synaptotagmin XIII NM_020826 3.04
CLCN3 chloride channel 3 NM_001829 2.69
RTN4RL1 reticulon 4 receptor-like 1 NM_178568 2.45
METAP2 methionyl aminopeptidase 2 NM_006838 2.11
PARD3 par-3 partitioning defective 3 
homolog (C. elegans)
NM_019619 2.00
SYK spleen tyrosine kinase NM_001135052 1.94
JAK2 Janus kinase 2 (a protein tyrosine 
kinase)
NM_004972 1.93
Inflammation specific transcripts (High in inflammation compared to tumor)
PTPRC protein tyrosine phosphatase, 
receptor type, C
NM_001846 2.61
DHODH dihydroorotate dehydrogenase NM_001361 2.56
KIAA0773 KIAA0773 gene product NM_001031690 2.38
COL4A2 collagen, type IV, alpha 2 NM_001846 2.31
PBX1 pre-B-cell leukemia transcription 
factor 1
NM_002585 1.70
RBP2 retinol binding protein 2, cellular NM_004164 1.66
HPX hemopexin NM_000613 1.64
CCL5 chemokine (C-C motif) ligand 5 NM_002985 1.63
RefSeq ID: Reference Sequence identity; The National Center for Biotechnology Information (NCBI); http://www.ncbi.nlm.nih.gov/RefSeq. The 
fold-changes display the regulation of expression of the particular gene in stellate cells that is upregulated with respect to comparator.Erkan et al. Molecular Cancer 2010, 9:88
http://www.molecular-cancer.com/content/9/1/88
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genic effects in HSC, thus, limiting its efficient systemic
use in the clinical setting [37].
In this context, our data provide valuable information
focusing on the subtle but important differences of liver
vs. pancreatic stellate cells that exist rather than their
similarities. We found collagen type 11a1 expression to
be highly specific for the PSC and almost absent in HSC.
Type XI collagen is a minor fibril-forming collagen that
assists in proper type II collagen fibril formation [38].
Col11a1 is mainly expressed in articular cartilage and the
vitreous fluid of the eye [39-43]. During embryogenesis,
Col11a1 expression is also detectable in many other
human fetal tissues including the bone [40]. Marshall and
type II Stickler syndromes are genetically transmitted dis-
eases that are caused by mutations in Col11a1 gene mani-
fested with sensory and skeletal abnormalities [44,45]. In
Col11a1 knockout mice, chondrocytes fail to fully differ-
entiate causing a chondrodystrophic phenotype with
skeletal abnormalities. These data show that Col11a1 is
essential for skeletal morphogenesis because it controls
type II collagen fibrillogenesis, chondrocyte maturation
and bone mineralization [46,47]. Importantly, in adult life
these tissues are not undergoing dynamic changes.
Therefore Coll11a1 may provide an interesting target for
conditional knockout to target PSC in order to assess
PSC contribution in conditions like chronic pancreatitis
or pancreatic cancer.
Buchholz et al. compared gene expression of human
HSC, PSC and skin fibroblasts [9]. Their data show that,
compared to dermal fibroblasts, HSC and PSC exhibit
great similarities in their transcriptional phenotypes and
possibly share a common origin [3,9]. Indeed, HSC and
PSC are activated by common cytokines, growth factors
and alcohol metabolites during development of tissue
fibrosis [3,7,30,48-50]. However, the fundamental differ-
ences in their microenvironments may condition these
cells to differentially respond to organ injury and cancer
[1,3,30]. For example, in contrast to hepatocellular carci-
Figure 9 Quantitative mRNA and protein expression analysis of CELSR3 and its localization in tissues. Quantitative real-time PCR (A) was per-
formed with the Light Cycler Fast Start DNA SYBR Green kit. Densitometric analysis of immunoblots (B) were performed using the ImageJ program 
provided by the National Institutes of Health. Optic densities were corrected for the individual background noise and the matching equal loading 
densities. Each column represents one patient. For each entity, stellate cells from four different patients were evaluated. The disease specific expres-
sion of CELSR3 is depicted in the last two columns of each graph. Tissues of primary pancreatic ductal adenocarcinoma (C, 200×), chronic pancreatitis 
(D, 200×), liver cirrhosis (E, 200×) and liver metastasis of pancreatic ductal adenocarcinoma (F, 200×) were immunostained with a specific antibody 
against CELSR3. Negative controls are shown as insets. Arrows show the stellate cells in the fibrotic parts of the tissues.
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noma, desmoplasia is a typical feature of pancreatic duc-
tal adenocarcinoma. This difference may result in part
due to the release of potent fibrogenic mediators by pan-
creatic cancer cells [1,19,30,51]. We have previously
shown that, compared to the primary tumor, liver metas-
tasis of PDAC elicit a weaker fibrogenic response in the
HSC that surround them. This observation can be due to
the differences of HSC and PSC, or it could, considering
the temporal sequence of events, merely reflect a shorter
cancer-HSC interaction [30]. Interestingly, we found
almost twice as much differentially regulated genes with
a n  o r g a n  s p e c i f i c  e x p r e s s i o n  p a t t e r n  a s  c o m p a r e d  t o
chronic inflammation or tumor related genes. Moreover,
differences in gene expression levels between HSC and
PCS were more pronounced compared to disease specific
stellate cells. These differences can be due to various fac-
tors. It may reflect that PSC and HSC do not share a com-
mon origin, or it may also suggest that chronic
inflammation and cancer develop in similar microenvi-
ronments created by the activated stroma of the respec-
tive organs.
In the clinical setting, chronic inflammatory conditions
of the liver (cirrhosis) and pancreas (chronic pancreatitis)
not only increase the incidence of cancer, but also consti-
tute diagnostic hurdles. Biopsies that do not show tumor
structures are not helpful in diagnosis since they are use-
less in exclusion of the tumor. However, identification of
tumor versus inflammation specific signatures of the
stroma may increase diagnostic accuracy of biopsies even
where tumor tissue is missed.
Conclusively, identification of inherent and acquired
differences in stellate cell transcriptome will improve cur-
rent understanding of stellate cell pathophysiology and
may facilitate the discovery of novel selective therapeutic
targets. Our data provide a new platform to understand
and possibly interfere with organ or disease specific
Figure 10 Quantitative mRNA and protein expression analysis of Pbx1 and its localization in tissues. Quantitative real-time PCR (A) was per-
formed with the Light Cycler Fast Start DNA SYBR Green kit. Densitometric analysis of immunoblots (B) were performed using the ImageJ program 
provided by the National Institutes of Health. Optic densities were corrected for the individual background noise and the matching equal loading 
densities. Each column represents one patient. For each entity, stellate cells from four different patients were evaluated. The disease specific expres-
sion of Pbx1 is depicted in the last two columns of each graph. Tissues of primary pancreatic ductal adenocarcinoma (C, 200×), chronic pancreatitis 
(D, 200×), liver cirrhosis (E, 200×) and liver metastasis of pancreatic ductal adenocarcinoma (F, 200×) were immunostained with a specific antibody 
against Pbx1. Negative controls are shown as insets. Arrows show the stellate cells in the fibrotic parts of the tissues.
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responses of stellate cells. Further research is warranted
to analyze the importance of these findings at functional
levels.
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